多价火鸡疱疹病毒重组疫苗对高致病性禽流感、传染性法氏囊病和新城疫病毒的效力
研究构建了表达禽流感病毒COBRA H5抗原的三种重组火鸡疱疹病毒载体疫苗(单独表达H5、联合表达IBDV VP2或NDV F蛋白),在接种鸡中评估其对高致病性禽流感、传染性法氏囊病和新城疫的临床保护效果。结果显示三种疫苗均提供90-100%针对三个不同进化分支HPAIV的临床保护,并显著降低攻毒后2天排毒鸡数和口腔排毒滴度;联合疫苗对IBDV和NDV分别提供100%临床保护。
要点
- 三种vHVT疫苗接种鸡对三个不同进化分支HPAIV均提供90-100%临床保护。
- 接种后4周多数鸡产生H5血凝抑制抗体,攻毒后抗体滴度显著升高。
- vHVT-IBD-AI和vHVT-ND-AI分别对IBDV和NDV提供100%临床保护。
核心结论
- 多价HVT载体疫苗可有效同时控制高致病性禽流感病毒和其他病毒感染。
研究设计与样本
- 研究构建了表达AIV COBRA H5的重组火鸡疱疹病毒疫苗vHVT-AI、vHVT-IBD-AI(联合IBDV VP2)和vHVT-ND-AI(联合NDV F蛋白),在接种鸡中评估免疫保护效果。
主要发现
- 三种vHVT疫苗接种鸡对三个不同进化分支HPAIV均提供90-100%临床保护,攻毒后2天排毒鸡数和口腔排毒滴度较模拟接种组显著降低。
- 接种后4周多数接种鸡具有H5血凝抑制抗体滴度,攻毒后抗体滴度显著升高。
- vHVT-IBD-AI疫苗对IBDV提供100%临床保护,vHVT-ND-AI疫苗对NDV提供100%临床保护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are an essential tool for the control of viral infections in domestic animals. We generated recombinant vector herpesvirus of turkeys (vHVT) vaccines expressing computationally optimized broadly reactive antigen (COBRA) H5 of avian influenza virus (AIV) alone (vHVT-AI) or in combination with virus protein 2 (VP2) of infectious bursal disease virus (IBDV) (vHVT-IBD-AI) or fusion (F) protein of Newcastle disease virus (NDV) (vHVT-ND-AI). In vaccinated chickens, all three vHVT vaccines provided 90-100% clinical protection against three divergent clades of high pathogenicity avian influenza viruses (HPAIVs), and significantly decreased number of birds and oral viral shedding titers at 2 days post-challenge compared to shams. Four weeks after vaccination, most vaccinated birds had H5 hemagglutination inhibition antibody titers, which significantly increased post-challenge. The vHVT-IBD-AI and vHVT-ND-AI vaccines provided 100% clinical protection against IBDVs and NDV, respectively. Our findings demonstrate that multivalent HVT vector vaccines were efficacious for simultaneous control of HPAIV and other viral infections.
引用
- Criado MF, Kassa A, Bertran K, et al. Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses. Vaccine. 2023. PMID: 37012117. doi:10.1016/j.vaccine.2023.03.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。